Imatinib Mesylate

Imatinib mesylate is a kinase inhibitor indicated for the treatment of:

  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase
  • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy
  • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
  • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
  • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown
  • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown
  • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)

Imatinib Mesylate ‐ Apotex

Size:
100 mg, 90 Tablets
NDC #:
60505-2900-09
Download:
PI
Size:
400 mg, 30 Tablets
NDC #:
60505-2901-03
Download:
PI

Imatinib Mesylate ‐ Sun Pharma

Size:
100 mg, 90 Tablets
NDC #:
47335-0472-81
Download:
PI
Size:
400 mg, 30 Tablets
NDC #:
47335-0475-83
Download:
PI